MedTrace Logo

The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.

NCT01733030 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2017-05-04

No results posted yet for this study

Summary

PROJECT SUMMARY:

PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred to as stimulus generalization has received surprisingly little empirical testing in the context of clinical anxiety in general, and PTSD more specifically. The current proposal represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant learning phenomenon across those with and without PTSD. The objective of this particular proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms associated with generalization of conditioned fear and 2) examine the pharmacologic modifiability of levels of generalization using a partial agonist at the NMDA receptor complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety cue) in animal studies.

Conditions

  • Post Traumatic Stress Syndrome

Interventions

DRUG

Seromycin

250 mg versus 500 mg versus placebo effects on conditioned fear generalization

DRUG

Seromycin

Sponsors & Collaborators

Principal Investigators

  • Shmuel Lissek, PhD · University of Minnesota

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-10-01
Completion
2015-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733030 on ClinicalTrials.gov